EP0591363A1 - Compositions pharmaceutiques contenant de la torasemide - Google Patents
Compositions pharmaceutiques contenant de la torasemideInfo
- Publication number
- EP0591363A1 EP0591363A1 EP92913781A EP92913781A EP0591363A1 EP 0591363 A1 EP0591363 A1 EP 0591363A1 EP 92913781 A EP92913781 A EP 92913781A EP 92913781 A EP92913781 A EP 92913781A EP 0591363 A1 EP0591363 A1 EP 0591363A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- parts
- weight
- torasemide
- pharmaceutical composition
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the invention relates to torasemide-containing pharmaceutical compositions which, for. B. are effective as prophylactic or therapeutic agents against hypertension and edema, or as diuretics.
- Torasemide [chemical name: l-isopropyl-3- (4-m-toluidino-3-pyridyl) sulfonyl) urea] is e.g. B. effective as a diuretic in the context of hypertension therapy.
- Orally administered preparations containing torasemide are produced by a generally customary process by adding, for example, sugar, starch, starch derivatives, cellulose, cellulose derivatives, mold release agents, non-stick agents or other customary auxiliaries; they are applied, for example, as tablets to which lactose, corn starch, silicon oxide or magnesium stearate is added (EP-A-0,212,537).
- compositions are desired in which the storage stability of the torase itself is improved, especially when stored over a longer period of time, changes in the appearance of the preparation caused by moisture absorption are avoided, and the absorption of the torasemide is avoided is further improved by the digestive tract and which have good bioavailability. It has been found that changes in the formulations which have occurred can be caused by corn starch present in the formulation. Accordingly, this invention aims to solve such problems as are encountered in the conventional art and to make better torasemide-containing preparations available for oral administration. To solve the problems described above, numerous commonly used components, such as. B. binders and disintegrants, tests carried out.
- torasemide-containing compositions which contain hydroxypropyl cellulose or polyvinylpyrrolidone (PVP) as binders, sodium croscarmellose or crospovidone as disintegrants and customary shaping agents, such as, for. B. lactose and / or crystalline cellulose and lubricants such as. B. magnesium stearate, have excellent properties as preparations for oral administration.
- PVP polyvinylpyrrolidone
- customary shaping agents such as, for. B. lactose and / or crystalline cellulose and lubricants such as. B. magnesium stearate
- the active ingredient, the binder and the disintegrant are to be used in certain ratios to one another.
- the invention therefore relates to pharmaceutical compositions containing torasemide or a compatible salt thereof, a binder selected from the products hydroxypropyl cellulose and polyvinylpyrrolidone (PVP), a disintegrant selected from the products sodium croscarmellose, crospovidone, calcium carboxymethyl cellulose, contain low-substituted hydroxypropyl cellulose, modified starch and sodium carboxymethyl starch and conventional shaping agents and lubricants.
- PVP polyvinylpyrrolidone
- a disintegrant selected from the products sodium croscarmellose, crospovidone, calcium carboxymethyl cellulose
- torasemide preferably the active ingredient in modification 1
- the torasemide salts are not subject to any particular restriction if they are pharmacologically acceptable substances; as examples, salts with organic acids, such as. B. acetic acid, suberic acid, maleic acid, fumaric acid, malic acid, tartaric acid or methanesulfonic acid, and salts with inorganic acids, such as. As hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
- hydroxypropyl cellulose is preferred as the binder; in particular, it was found that especially those with a high degree of substitution are suitable.
- the degree of substitution of such a highly substituted hydroxypropyl cellulose is normally 50-80%, preferably 60-70%, expressed as a content (%) of hydroxypropoxyl groups.
- Commercial hydroxypropyl cellulose is used specifically.
- Polyvinylpyrrolidone is also preferred.
- Sodium croscarmellose, crospovidone, calcium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, modified starch or sodium carboxymethyl starch are preferably used as disintegrants.
- sodium croscarmellose or crospovidones are preferred.
- Sodium croscarmellose is usually understood to mean sodium carboxy ethyl cellulose, crosslinked, crosprovidone polyvinylpyrrolidone, crosslinked.
- a modified starch is preferably a starch converted to the position.
- Shaping agents or lubricants will also be added to the pharmaceutical composition according to this invention; as shaping agents are preferred z.
- the mixing ratio of the individual components in the pharmaceutical composition of this invention is normally 0.1-50 parts (here and hereinafter: parts by weight), preferably 0.5-15 parts, more preferably 1-10 parts of torasemide; 1-10 parts, preferably 2-5 parts binder; 1-20 parts, preferably 3-15 parts, more preferably 5-10 parts of disintegrant.
- the proportions of the other components that are mixed into the pharmaceutical composition of this invention are 10-150 parts, preferably 70-140 parts, more preferably 100-130 parts of shaping agents, and 0.1-5 parts, preferably 0.2-2 Parts, more preferably 0.5-1.5 parts of lubricant.
- the pharmaceutical composition of this invention is e.g. B. as a prophylactic or therapeutic against hypertension and edema, or ideally administered orally as a diuretic.
- the pharmaceutical composition of this invention is processed into a powder, granule, tablet or pellet by conventional methods.
- the application of the pharmaceutical composition according to the invention varies depending on the sex, body weight, age, disease state, etc. of the patient; Usually, a daily dose of approximately 1 to 200 mg of torasemide is administered to an adult, preferably 1 to 30 mg, divided into one to several times a day.
- 40 g torasemide were mixed with 1,064 g lactose, 32 g hydroxypropyl cellulose (content of hydroxypropoxyl groups 62%) and 24 g sodium croscarmellose, pelleted with water, dried and then sieved. 12.9 g of sodium croscarmellose and 3.2 g of magnesium stearate were mixed with 466 g of this substance and the whole was then processed into tablets by a customary process. About 2,300 tablets containing 4 mg of torasemide per tablet were produced in this way.
- the numbers indicate the weight (mg) of the ingredients in the tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Une composition pharmaceutique stable au stockage contient de la torasémide en tant que substance active, un liant et un agent désintégrant, ainsi que des agents de moulage et de lubrification usuels.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP181820/91 | 1991-06-25 | ||
JP18182091A JP3586471B2 (ja) | 1991-06-25 | 1991-06-25 | トラセミド含有医薬組成物 |
PCT/EP1992/001437 WO1993000097A1 (fr) | 1991-06-25 | 1992-06-25 | Compositions pharmaceutiques contenant de la torasemide |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0591363A1 true EP0591363A1 (fr) | 1994-04-13 |
Family
ID=16107395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92913781A Withdrawn EP0591363A1 (fr) | 1991-06-25 | 1992-06-25 | Compositions pharmaceutiques contenant de la torasemide |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0591363A1 (fr) |
JP (1) | JP3586471B2 (fr) |
WO (1) | WO1993000097A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
ES2364145T3 (es) * | 1996-11-15 | 2011-08-25 | Ajinomoto Co., Inc. | Composición de nateglinida en comprimidos. |
DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
MXPA04006977A (es) * | 2002-01-16 | 2005-04-19 | Kowa Co | Composicion farmaceutica que comprende acido 2,2-dicloro-12-(4-clorofenil)-dodecanoico. |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
US7109242B2 (en) | 2003-05-23 | 2006-09-19 | Kowa Company, Ltd. | Carboxylic compound and medicine comprising the same |
ES2244324B1 (es) * | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | Composiciones diureticas de liberacion prolongada. |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
EP2417969A1 (fr) | 2004-10-21 | 2012-02-15 | Aptalis Pharmatech, Inc. | Compositions pharmaceutiques à saveur masquée avec substances porogènes gastrosolubles |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
JP5309262B2 (ja) | 2009-12-02 | 2013-10-09 | アプタリス ファーマ リミテッド | フェキソフェナジン・マイクロカプセル及びそれを含む組成物 |
JP5617382B2 (ja) | 2010-06-28 | 2014-11-05 | トヨタ紡織株式会社 | インテークマニホールド |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
-
1991
- 1991-06-25 JP JP18182091A patent/JP3586471B2/ja not_active Expired - Lifetime
-
1992
- 1992-06-25 WO PCT/EP1992/001437 patent/WO1993000097A1/fr not_active Application Discontinuation
- 1992-06-25 EP EP92913781A patent/EP0591363A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9300097A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP3586471B2 (ja) | 2004-11-10 |
JPH05952A (ja) | 1993-01-08 |
WO1993000097A1 (fr) | 1993-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3880762T2 (de) | Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung. | |
DE3780222T2 (de) | Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung. | |
DE69521799T2 (de) | Polymer umhüllte tablette enthaltend amoxicillin und clavulanat | |
DE69106154T2 (de) | Verzögerte Freisetzung mit hoch- und niedrigviskoser HPMC. | |
DE69903404T2 (de) | Celecoxib-Zusammensetzungen | |
DE3779933T2 (de) | Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung. | |
EP0128482B1 (fr) | Formes galéniques d'antidiabétiques orales et procédé de leur préparation | |
DE3887179T2 (de) | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. | |
DE69623634T2 (de) | Pharmazeutische zusammensetzung von l-dopa ethyl ester | |
DE69721749T2 (de) | Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung | |
EP0265848A1 (fr) | Préparations médicamentaires pour l'administration orale contenant à dose unitaire de 10 à 240 mg d'une dihydropyridine | |
DD224216A5 (de) | Verfahren zur herstellung von oral antidiabetisch wirkenden zubereitungsformen | |
EP0591363A1 (fr) | Compositions pharmaceutiques contenant de la torasemide | |
DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
DE3650716T2 (de) | Trimethoprim und ein Sulfonamid enthaltende Tabletten | |
EP1077681B1 (fr) | Preparation pharmaceutique contenant de la levothyroxine sodique | |
EP1094841B1 (fr) | Preparation pharmaceutique contenant de la levothyroxine | |
EP0625355B2 (fr) | Comprimé à biodisponibilité améliorée contenant l'acide dichlorométhylène-diphosphonique en tant qu'ingrédient actif | |
EP0722719B1 (fr) | Procédé de fabrication de préparations à base de flavano-lignanes | |
DE69108007T2 (de) | Verfahren zur herstellung einer einen wärme-, licht- und feuchtigkeit empfindlichen wirkstoff mit einer monoklinisch kristallinen struktur enthaltenden tabletten oder dragee zusammensetzung. | |
DE69433012T2 (de) | Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac | |
DE60030654T2 (de) | Verwendung von Lasofoxifen | |
EP0088098B1 (fr) | Composition et procede de preparation de tablettes se desagregeant rapidement en milieu aqueux | |
DE69733752T2 (de) | Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz | |
DE2446058A1 (de) | Galenische zubereitung fuer die allopurinol-dauertherapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19931123 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19951228 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19960508 |